Earnings ·
Precigen reported second quarter 2026 financial results, achieving net income of $20.1 million ($0.06 per basic share)…
PGENPrecigen, Inc.
Precigen reported second quarter 2026 financial results, achieving net income of $20.1 million ($0.06 per basic share) compared to a net loss in the prior year period. Total revenues reached $55.0 million, driven by PAPZIMEOS product revenue of $53.1 million, which more than doubled from the previous quarter. The company reported cash, cash equivalents, and investments totaling $38.7 million as of June 30, 2026, projecting a path to cash flow break-even by year-end 2026. Additionally, the FDA granted PAPZIMEOS seven-year market exclusivity, and patient hub enrollment exceeded 500 patients. Precigen is a commercial-stage biopharmaceutical company specializing in precision medicines for difficult-to-treat diseases.